Skip to Main Content

2,480

Views

0

CrossRef citations to date

0

Altmetric

Oncology

US cost-effectiveness analysis of polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma

Matthew Matasara Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USACorrespondence[email protected]
View further author information

,

Anthony Masaquelb Genentech, Inc, South San Francisco, CA, USAView further author information

,

Rodrigo S. Hoc F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information

,

Aino Launonenc F. Hoffmann-La Roche Ltd, Basel, SwitzerlandView further author information

,

Carmen D. Ngb Genentech, Inc, South San Francisco, CA, USAView further author information

,

Rongrong Wangb Genentech, Inc, South San Francisco, CA, USAView further author information

,

David Foxb Genentech, Inc, South San Francisco, CA, USAView further author information

,

Farah Hossainb Genentech, Inc, South San Francisco, CA, USAView further author information

,

Jia Lib Genentech, Inc, South San Francisco, CA, USAView further author information

&

John M. Burked Rocky Mountain Cancer Centers/US Oncology, Aurora, CO, USAView further author information